Lakefront Biotherapeutics (GLPGF) Profit After Tax Growth (3y) (2017 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Profit After Tax Growth (3y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.13 Bn | 197.14 Bn | 7.24 Bn | 19.87% |
| 2 | Gilead Sciences | 181.20 Bn | 178.03 Bn | 6.22 Bn | -129.22% |
| 3 | Vertex Pharmaceuticals | 132.23 Bn | 124.38 Bn | 2.84 Bn | 6.30% |
| 4 | Regeneron Pharmaceuticals | 82.91 Bn | 74.92 Bn | 3.93 Bn | 10.23% |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | 91.31% |
| 6 | Moderna | 55.02 Bn | 49.89 Bn | 52.00 Mn | 17.25% |
| 7 | Alnylam Pharmaceuticals | 34.05 Bn | 30.74 Bn | 992.69 Mn | 37.44% |
| 8 | Biogen | 31.30 Bn | 30.01 Bn | 1.96 Bn | -45.23% |
| 9 | Roivant Sciences | 30.18 Bn | 30.18 Bn | 1.16 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | 26.95% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 26.95% |
| Mar 31, 2026 | -12.01% |
| Dec 31, 2025 | 1,109.97% |
| Sep 30, 2025 | -134.53% |
| Jun 30, 2025 | -80.57% |
| Mar 31, 2025 | -121.05% |
| Dec 31, 2024 | 980.11% |
| Sep 30, 2024 | 44.24% |
| Jun 30, 2024 | 35.64% |
| Mar 31, 2024 | 102.86% |
| Dec 31, 2023 | 667.50% |
| Sep 30, 2023 | 30.67% |
| Jun 30, 2023 | 36.35% |
| Mar 31, 2023 | 34.47% |
| Dec 31, 2022 | -18.26% |
| Sep 30, 2022 | -62.21% |
| Jun 30, 2022 | 27.41% |
| Mar 31, 2022 | 35.36% |
| Dec 31, 2021 | -78.46% |
| Sep 30, 2021 | -116.66% |